Scarica l'app Stockscreener
123.77
5.53%
6.49
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MIRM Giù?
Forum
Previsione
Precedente Chiudi:
$117.28
Aprire:
$116.51
Volume 24 ore:
3.35M
Relative Volume:
3.33
Capitalizzazione di mercato:
$7.55B
Reddito:
$521.31M
Utile/perdita netta:
$-23.36M
Rapporto P/E:
-258.88
EPS:
-0.4781
Flusso di cassa netto:
$54.87M
1 W Prestazione:
+15.53%
1M Prestazione:
+25.15%
6M Prestazione:
+56.16%
1 anno Prestazione:
+144.80%
Intervallo 1D:
$113.41
$124.44
Intervallo di 1 settimana:
$105.18
$124.44
Portata 52W:
$47.89
$124.44
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
Nome
Mirum Pharmaceuticals Inc
Settore
Industria
Telefono
650-667-4085
Indirizzo
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
Compare MIRM vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
123.77 | 7.55B | 521.31M | -23.36M | 54.87M | -0.4781 |
VRTX
Vertex Pharmaceuticals Inc
|
491.34 | 124.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 66.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.18 | 55.17B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.37 | 38.90B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 38.71B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-09-24 | Iniziato | TD Cowen | Buy |
| 2025-08-11 | Ripresa | Stifel | Buy |
| 2025-05-19 | Ripresa | H.C. Wainwright | Buy |
| 2024-04-17 | Iniziato | Stifel | Buy |
| 2023-12-18 | Reiterato | H.C. Wainwright | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-11-13 | Iniziato | Morgan Stanley | Overweight |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-17 | Ripresa | Evercore ISI | Outperform |
| 2023-09-20 | Iniziato | JMP Securities | Mkt Outperform |
| 2022-09-01 | Iniziato | Citigroup | Buy |
| 2021-09-20 | Iniziato | JP Morgan | Overweight |
| 2020-08-07 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | Iniziato | H.C. Wainwright | Buy |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-06-25 | Iniziato | Robert W. Baird | Outperform |
| 2019-08-12 | Iniziato | Citigroup | Buy |
| 2019-08-12 | Iniziato | Evercore ISI | Outperform |
| 2019-08-12 | Iniziato | Guggenheim | Buy |
| 2019-08-12 | Iniziato | ROTH Capital | Buy |
| 2019-08-12 | Iniziato | Raymond James | Outperform |
Mostra tutto
Mirum Pharmaceuticals Inc Borsa (MIRM) Ultime notizie
Enterprise value to revenue forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Price to sales forward of Mirum Pharmaceuticals, Inc. – NASDAQ:MIRM - TradingView
Understanding Momentum Shifts in (MIRM) - Stock Traders Daily
Price to earnings forward of Mirum Pharmaceuticals, Inc. – HAM:08D - TradingView
MIRM, INCY report positive rare disease data as FDA begins NDA review - MSN
MIRM Forecast — Price Target — Prediction for 2027 - TradingView
Mirum Pharmaceuticals Stock Surges 18%, With A 8-Day Winning Spree - Trefis
Mirum Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRM) - TradingView
08D Forecast — Price Target — Prediction for 2027 - TradingView
Is Mirum Pharmaceuticals, Inc. (MIRM) Emerging as a Rare Disease Growth Story After New FOP Data? - Insider Monkey
Mirum Pharmaceuticals Hits New 52-Week High of $119.49, Up 359% - MarketsMojo
Mirum Pharmaceuticals stock hits all-time high at 114.99 USD - Investing.com
Mirum Pharmaceuticals stock hits all-time high at 114.99 USD By Investing.com - Investing.com India
Mirum Pharmaceuticals stock pushes toward 52-week high amid strong bullish momentum - Traders Union
Values First Advisors, Inc.'s Mirum Pharmaceuticals Inc(MIRM) Holding History - GuruFocus
Mirum Shareholders Approve Directors, Auditors and Compensation - The Globe and Mail
Mirum Pharmaceuticals StockAnalyst views and sector check at week’s end - AD HOC NEWS
Insider Sell: Jolanda Howe Sells Shares of Mirum Pharmaceuticals Inc (MIRM) - GuruFocus
Mirum (MIRM) SVP Jolanda Howe sells 2,594 shares under Rule 10b5-1 plan - Stock Titan
Mirum Pharmaceuticals, Inc. (MIRM) reports Q1 loss, beats revenue estimates - MSN
Mirum Pharmaceuticals (MIRM) stockholders back 2026 directors, auditor and pay package - Stock Titan
Mirum Pharmaceuticals Inc (MIRM) Institutional Confidence - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mirum Pharmaceuticals Inc (MIRM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Mirum (MIRM) director Michael G. Grey awarded RSUs and $101 stock options - Stock Titan
Mirum Pharmaceuticals (MIRM) director granted new options and deferred stock units - Stock Titan
Director at Mirum (MIRM) awarded deferred stock units and options - Stock Titan
Mirum Pharmaceuticals Inc (MIRM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MIRM (NASDAQ) director plans sale of 2,594 shares via Morgan Stanley - Stock Titan
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review (Revised) - TradingView
Mirum Pharmaceuticals (MIRM) director granted options and 1,980 deferred stock units - Stock Titan
Avoiding Lag: Real-Time Signals in (MIRM) Movement - Stock Traders Daily
MIRM Maintained by Citizens -- Price Target Raised to $146 - GuruFocus
MIRM, INCY Report Positive Rare Disease Data as FDA Begins NDA Review - TradingView
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Citizens raises Mirum Pharmaceuticals stock price target on drug deal By Investing.com - Investing.com Australia
Citizens raises Mirum Pharmaceuticals stock price target on drug deal - Investing.com
Mirum and Incyte's zilurgisertib shows positive phase 2 data in FOP - MSN
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - The Malone Telegram
Mirum Pharmaceuticals, Inc. and Incyte Report Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - marketscreener.com
Here's what key metrics tell us about Mirum Pharmaceuticals (MIRM) Q1 earnings - MSN
MIRM Maintains Overweight Rating -- Price Target Raised to $150 - GuruFocus
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Mirum Pharmaceuticals (NASDAQ:MIRM) Given New $150.00 Price Target at Morgan Stanley - MarketBeat
Why is Mirum Pharmaceuticals (MIRM) down 10.1% since last earnings report? - MSN
Insider Selling: Mirum Pharmaceuticals (NASDAQ:MIRM) CFO Sells 5,000 Shares of Stock - MarketBeat
Mirum Pharmaceuticals Inc Azioni (MIRM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.36%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):